|

STC-1010 + IS regimen + SOC therapy Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Brenus Pharma1

Indications

  • Unresectable Locally Advanced Colorectal Cancer1
  • Unresectable Metastatic Colorectal Cancer1
  • Cancer1

Baltimore, Maryland1 trial

First-in-human Trial of STC-1010, an Immunotherapy, in Patients With Unresectable Locally Advanced or Metastatic Colorectal Cancer

Johns Hopkins

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.